Brought to you by 
Sangamo issues $996k in stock, to pay earn-outs for gene therapy firm Ceregene
27 Aug 2020
Executive Summary
Sangamo BioSciences Inc. (protein medicines targeting DNA) has acquired Ceregene Inc., a private gene therapeutics developer. Sangamo is issuing 100k shares valued at $996k up front, representing less than 0.2% of its outstanding stock. Ceregene may also receive a certain amount of cash and cash equivalent minus certain liabilities and expenses.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sangamo issues $996k in stock, to pay earn-outs for gene therapy firm Ceregene
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice